OR WAIT null SECS
The team joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments and expands capabilities in genomic-based drug development.
Parexel has expanded services and capabilities in genomic-based drug development with its Genomic Medicine team. The team is comprised of more than 15 scientists with combined expertise in genomics, drug discovery, and drug development, who joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments. The team will meet clients’ expected increased needs for the number of personalized medicines that will require genomic information to inform decision-making on the clinical utility and value for the intended patient population.
Read the full release.